The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested identity is unambiguous: human MAP2K4 encodes dual-specificity mitogen-activated protein kinase kinase 4 (MKK4), also called MEK4, JNKK1, SEK1, SAPKK1, and JNK-activating kinase 1. UniProt P45985 is a 399-amino-acid intracellular MAPK kinase belonging to the STE/MAP2K branch of the protein-kinase superfamily. This identity, organism, length, architecture, and substrate profile agree with the supplied UniProt record; the literature does not indicate that the requested symbol refers here to another organism or protein. MAP2K4 must not be confused with MAP2K7/MKK7, its cooperating JNK kinase, or MAP4K4, an upstream MAP4K-family enzyme. (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, gehi2022intrinsicdisorderin pages 15-17, gehi2022intrinsicdisorderin pages 17-18)
Its primary biochemical function is to use ATP to phosphorylate activation-loop threonine and tyrosine residues in stress-activated MAPKs. Its best-supported direct physiological substrates are JNK1–3 and members of the p38 MAPK family. For JNK, MKK4 preferentially phosphorylates the tyrosine—Tyr185 in the canonical JNK1 numbering—whereas MKK7 preferentially phosphorylates Thr183. MKK4 can also phosphorylate the p38 Thr180-Gly-Tyr182 motif. Thus, MKK4 is a stress-responsive signaling relay positioned between several MAP3Ks and the JNK/p38 effector systems, rather than a constitutively active metabolic enzyme. (ho2003adockingsite pages 1-1, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, gehi2022intrinsicdisorderin pages 15-17)
The most important recent translational development is HRX215, an orally active, selective MKK4 inhibitor. A 2024 Cell study showed enhanced liver regeneration in mice and pigs, survival after otherwise lethal porcine hepatectomy, and favorable safety and pharmacokinetics in 48 healthy volunteers. These results constitute strong preclinical and phase-I safety evidence, but not yet proof of therapeutic efficacy in patients with liver failure. (zwirner2024firstinclassmkk4inhibitors pages 11-13, zwirner2024firstinclassmkk4inhibitors pages 10-11, zwirner2024firstinclassmkk4inhibitors pages 3-5, zwirner2024firstinclassmkk4inhibitors pages 1-3)
MAP2K4 is distinct from MAP2K7, although both activate JNK. MKK7 is comparatively JNK selective and favors phosphorylation of JNK Thr183, while MKK4 favors Tyr185 and additionally activates p38. MAP4K4 is a different kinase tier and family; evidence retrieved for MAP2K4 was not conflated with MAP4K4 literature. (ho2003adockingsite pages 1-1, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, gehi2022intrinsicdisorderin pages 15-17)
The reaction can be summarized as:
ATP + MAPK protein–OH → ADP + MAPK protein–O-phosphate
MKK4 is termed “dual specificity” because its kinase domain can phosphorylate both threonine and tyrosine residues in MAPK activation loops. This does not mean that it broadly phosphorylates arbitrary Ser/Thr and Tyr proteins; recognition is strongly constrained by MAPK docking interactions and activation-loop sequence. (ho2003adockingsite pages 1-1, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4)
The evidence includes direct binding, peptide competition and in-vitro kinase experiments, not merely pathway co-occurrence. Mutation of the MKK4 docking site reduces JNK/p38 binding, while docking peptides inhibit MKK4-dependent phosphorylation of JNK1. (ho2003adockingsite pages 1-1, ho2003adockingsite pages 3-4)
MKK4 has the canonical bilobed protein-kinase fold: a smaller N-terminal lobe, larger predominantly α-helical C-terminal lobe, intervening hinge, ATP-binding cleft, glycine-rich loop, HRD catalytic loop, DFG magnesium-binding segment and flexible activation loop. Public structures include PDB 3ALN, 3ALO and 3VUT; 3ALN resolves residues 80–399 at 2.30 Å. (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, gehi2022intrinsicdisorderin pages 17-18)
Three regions organize signal transfer:
Upstream kinases phosphorylate the MKK4 activation-loop Ser257-X-Ala-Lys-Thr261 motif. Ser257 is essential for activation, while Thr261 is needed for full activity. Relevant upstream kinase groups include the ASK, MEKK, MLK and TAK families. This modular architecture—MAP3K recruitment at the C terminus, catalysis in the central domain and substrate recruitment at the N terminus—helps preserve signaling specificity despite the conserved ATP pockets of MAPK-family enzymes. (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4)
A concise pathway model is:
cellular stress/cytokines → MAP3K → MKK4 → JNK and/or p38 → transcriptional and cytoplasmic effectors.
Reported activating contexts include oxidative and osmotic stress, heat shock, UV/genotoxic stress, inflammatory cytokines and some growth-factor signals. Activated JNK subsequently regulates substrates including c-Jun/AP-1 components, ATF2 and other nuclear or cytoplasmic proteins; p38 supplies an overlapping but distinct stress-response output. Signal amplitude, duration, scaffold usage, cell lineage and cooperation with MKK7 determine whether the outcome is adaptation, proliferation, differentiation, arrest or apoptosis. (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, zhao2026advancesinsmallmolecule pages 3-5)
MKK4 consequently participates in:
Some broad biological annotations remain context dependent. For example, older work assigned MKK4 major T-cell survival/proliferation functions, whereas newer loss-of-function studies found little effect on some T-cell proliferative and antiviral responses. It is therefore safer to annotate MKK4 as a stress-activated JNK/p38 relay than to assign it an invariant immune-cell phenotype. (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4)
MKK4 is a soluble intracellular kinase rather than a secreted, transmembrane or organelle-resident protein. Cellular studies report both cytoplasmic and nuclear MKK4, but the available evidence does not justify assigning one universal compartment. Its working localization is best annotated as cytoplasmic and nuclear, dynamic and cell-context dependent. Activated downstream JNK and p38 can translocate to the nucleus, so nuclear pathway output does not necessarily imply that all MKK4 catalysis occurs there. (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, ahn2011map2k4functionsas pages 1-2)
Accordingly, the most defensible functional-localization statement is: MKK4 carries out substrate phosphorylation within intracellular stress-signaling complexes, with substantial cytoplasmic signaling and reported nuclear presence, rather than at the plasma membrane or outside the cell.
MAP2K4 should not be annotated simply as either an oncogene or a tumor-suppressor gene. A 2023 expert review concluded that its cancer role is tissue- and state-dependent. MAP2K4 loss has been reported in approximately 7–10% of epithelial cancers, and loss-of-function mutations were identified in 11 of 356 tumors in an early sequencing series. Conversely, elevated MKK4 signaling has been associated with aggressive or metastatic prostate, ovarian and some breast-cancer contexts. (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2)
Direct lung-adenocarcinoma experiments support tumor suppression: conditional Map2k4 loss increased multiplicity and accelerated growth of KRAS-driven mouse lung tumors, while MKK4 suppressed invasion in KRAS/TP53-mutant cells. Eight of 11 tested cancer-associated variants reduced protein stability or kinase activity. One proposed mechanism involved restraint of PPARγ2 expression. (ahn2011map2k4functionsas pages 1-2, ahn2011map2k4functionsas pages 4-5, ahn2011map2k4functionsas pages 2-4)
These apparently opposing findings are biologically plausible because MKK4 feeds two pleiotropic systems, JNK and p38. Different MAP3Ks, scaffolds, MKK7 availability, downstream isoforms and oncogenic backgrounds can redirect the same kinase toward apoptosis, growth restraint, survival or motility. Open Targets likewise associates MAP2K4 with breast, colorectal and pancreatic adenocarcinoma and neurodegenerative disease, but such aggregate associations establish relevance rather than causal direction. (OpenTargets Search: -MAP2K4)
MAP2K4 genotype or abundance alone is unlikely to be a universal therapeutic biomarker. Functional pathway state—including MKK7/JNK and p38 activity, tissue type, stress context and tumor genotype—should be measured before inferring whether inhibition or restoration would be beneficial.
The major 2023–2024 advance was movement from tool inhibitors toward a selective clinical candidate. The 2023 inhibitor review identified MKK4 as a promising but challenging target because its ATP pocket resembles MKK7 and because chronic pathway inhibition could have opposing effects across tissues and cancers. (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4)
In March 2024, Zwirner and colleagues reported HRX215 in Cell. The compound had two-digit-nanomolar MKK4 potency and greater than 100-fold selectivity over JNK1, BRAF and MKK7. NMR-guided studies supported direct kinase-pocket binding, and human PBMC assays demonstrated cellular target engagement. (zwirner2024firstinclassmkk4inhibitors pages 7-8)
Mechanistically, MKK4 inhibition in injured hepatocytes did not simply switch off all stress signaling. It redirected signaling toward MKK7–JNK1–ATF2/ELK1, producing a pro-survival and pro-regenerative transcriptional state. Little proliferation was induced in uninjured liver, suggesting dependence on an existing regenerative stress signal. In carcinoma models, by contrast, HRX215 reduced rather than stimulated proliferation, illustrating the pathway’s context dependence. (zwirner2024firstinclassmkk4inhibitors pages 10-11, zwirner2024firstinclassmkk4inhibitors pages 3-5, tchorz2024prometheus2.0druginduced pages 1-2)
The placebo-controlled phase-I study enrolled 48 healthy men across six treatment groups. There were no severe or serious adverse events; mild-to-moderate adverse events occurred in 36.1% of HRX215 recipients versus 41.7% with placebo. Exposure increased dose proportionally. Food delayed median time to maximum concentration from 1.2 to 3.9 hours while increasing Cmax 1.76-fold and AUC 2.09-fold. These findings support tolerability and oral development but do not demonstrate regeneration or survival benefit in patients. (zwirner2024firstinclassmkk4inhibitors pages 11-13, zwirner2024firstinclassmkk4inhibitors pages 1-3)
The intended real-world applications are prevention or treatment of post-hepatectomy liver failure, enabling more extensive oncological resections, and improving regeneration of small-for-size liver grafts. Registered development includes a recruiting phase-I/II study after minor or major liver resection (NCT06638502, planned enrollment 80) and a planned phase-II study after portal-vein embolization for colorectal liver metastasis (NCT07612007, planned enrollment 80). Trial status and enrollment targets should be checked in the registry before clinical use; HRX215 remains investigational.
The following table separates established molecular annotation from context-dependent and translational findings.
| Annotation aspect | Best-supported conclusion | Key experimental evidence | Source/year |
|---|---|---|---|
| Identity | MAP2K4 encodes human MKK4 (MEK4/JNKK1/SEK1), a 399-aa dual-specificity MAP kinase kinase; UniProt P45985. It is distinct from MKK7/MAP2K7 and MAP4K4. | Protein annotation and biochemical literature consistently identify P45985 as the 399-aa human MAP2K that activates stress-responsive MAPKs. | Gehi et al., 2022, https://doi.org/10.1007/s00018-022-04230-4; Katzengruber et al., 2023, https://doi.org/10.3390/ijms24087495 (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, gehi2022intrinsicdisorderin pages 15-17) |
| Family and domains | MKK4 has a canonical bilobed protein-kinase fold, an N-terminal MAPK-docking D-domain (residues 37–57), a protein-kinase domain (102–367), and a C-terminal MAP3K-binding DVD domain (364–387). | The N-terminal docking site is necessary and sufficient for high-affinity binding to JNK1–3 and p38α/β; PDB 3ALN resolves residues 80–399 at 2.30 Å. | Ho et al., 2003, https://doi.org/10.1074/jbc.M304229200; Gehi et al., 2022 (ho2003adockingsite pages 1-1, gehi2022intrinsicdisorderin pages 17-18, ho2003adockingsite pages 3-4) |
| Activation mechanism | Upstream MAP3Ks activate MKK4 by phosphorylating its Ser257-X-Ala-Lys-Thr261 activation-loop motif. Ser257 is essential, while Thr261 is required for full activity. | Mutational, structural, and kinase studies support phosphorylation-dependent activation of the flexible kinase activation loop. | Katzengruber et al., 2023, https://doi.org/10.3390/ijms24087495 (katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4) |
| Catalytic function | MKK4 transfers phosphate from ATP to both threonine and tyrosine residues in MAPK activation loops; its direct physiological substrates are principally JNK1–3 and p38 MAPKs. | In-vitro kinase and docking experiments demonstrate MKK4-dependent phosphorylation of JNK1 and p38, consistent with EC 2.7.12.2 dual-specificity activity. | Ho et al., 2003; Krishna et al., 2013; Katzengruber et al., 2023 (ho2003adockingsite pages 1-1, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4) |
| JNK specificity | MKK4 preferentially phosphorylates Tyr185 in the JNK Thr183-Pro-Tyr185 motif; MKK7 preferentially phosphorylates Thr183. Efficient cellular JNK activation commonly integrates both inputs. | Direct docking and phosphorylation studies show MKK4 binding to JNK1–3 and a relative preference for the tyrosine site, distinguishing it from MKK7. | Ho et al., 2003; Gehi et al., 2022; Itah et al., 2023, https://doi.org/10.1073/pnas.2218373120 (ho2003adockingsite pages 1-1, gehi2022intrinsicdisorderin pages 15-17) |
| p38 specificity | Unlike JNK-selective MKK7, MKK4 can phosphorylate the p38 Thr180-Gly-Tyr182 activation motif; substrate docking is documented for p38α and p38β. | The MKK4 D-site binds p38α/β, and biochemical kinase assays use p38 as a direct MKK4 substrate. | Ho et al., 2003; Katzengruber et al., 2023 (ho2003adockingsite pages 1-1, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4) |
| Upstream inputs and pathway position | MKK4 is a second-tier MAP2K activated by MAP3Ks in the ASK, MEKK, MLK, and TAK families during oxidative, osmotic, genotoxic, heat, cytokine, and related stress signaling. MAP3Ks dock through the C-terminal DVD region. | Biochemical and pathway studies place MKK4 between stress-responsive MAP3Ks and JNK/p38; its N-terminal D-site recruits downstream MAPKs. | Katzengruber et al., 2023 (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4) |
| Cellular location | MKK4 is an intracellular, non-membrane kinase reported in both cytoplasmic and nuclear fractions; however, strong MKK4-specific evidence defining a fixed compartment is limited. Localization should therefore be treated as dynamic and context-dependent, with signaling output also propagated by activated JNK/p38 translocation. | Available experimental literature supports nuclear and cytoplasmic staining in cellular models, but recent authoritative reviews do not establish a single dominant compartment or a universal stimulus-dependent trafficking mechanism for MKK4 itself. | Ahn et al., 2011, https://doi.org/10.1128/MCB.05562-11; Katzengruber et al., 2023 (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, ahn2011map2k4functionsas pages 1-2) |
| Cancer duality | MKK4 is not uniformly oncogenic or tumor suppressive. MAP2K4 loss can promote lung and other epithelial cancers, whereas elevated MKK4 signaling can support invasion/metastasis in prostate, ovarian, and some breast-cancer contexts. | Conditional Map2k4 loss accelerated KRAS-driven lung tumors; 8 of 11 tested cancer-associated variants impaired stability or activity. Reviews report MAP2K4 loss in 7–10% of epithelial cancers, but also summarize prometastatic settings. | Ahn et al., 2011; Katzengruber et al., 2023 (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, ahn2011map2k4functionsas pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2) |
| HRX215 potency and mechanism | HRX215 is an orally active, first-in-class MKK4 inhibitor with two-digit-nanomolar potency and >100-fold selectivity over JNK1, BRAF, and MKK7. In injured hepatocytes, MKK4 inhibition redirects signaling toward a pro-regenerative MKK7–JNK1–ATF2/ELK1 program. | NMR-guided binding studies, kinase selectivity panels, human-PBMC target-engagement assays, and genetic MKK4 suppression support on-target activity and pathway rewiring. | Zwirner et al., 2024, https://doi.org/10.1016/j.cell.2024.02.023 (zwirner2024firstinclassmkk4inhibitors pages 3-5, zwirner2024firstinclassmkk4inhibitors pages 7-8) |
| Mouse liver regeneration | After partial hepatectomy, hepatocyte proliferation increased from 4.93% with vehicle to 15.38%, 15.15%, and 26.3% at 0.4, 2, and 10 mg/kg HRX215, respectively; benefit was also observed in fibrotic and toxic-injury models. | Dose-response experiments measured proliferating hepatocytes and showed protection from CCl4-associated hepatocyte death. | Zwirner et al., 2024 (zwirner2024firstinclassmkk4inhibitors pages 7-8) |
| Pig liver regeneration and survival | After 80% hepatectomy, regenerated volume at 43 h was 251.8 ± 13.6 mL with HRX215 versus 160.0 ± 23.5 mL with placebo. After otherwise lethal 85% hepatectomy, 4/6 pretreated and 5/6 post-treated pigs survived, whereas no placebo animal completed the experiment without euthanasia. | Large-animal studies documented greater regeneration and attenuation of hyperammonemia, intracranial-pressure elevation, bilirubin/INR abnormalities, and liver injury. | Zwirner et al., 2024 (zwirner2024firstinclassmkk4inhibitors pages 11-13, zwirner2024firstinclassmkk4inhibitors pages 10-11) |
| Phase I safety and pharmacokinetics | A placebo-controlled first-in-human study enrolled 48 healthy men. No severe or serious adverse events occurred; mild-to-moderate adverse-event rates were 36.1% with HRX215 versus 41.7% with placebo. Exposure was dose proportional; food increased Cmax 1.76-fold and AUC 2.09-fold. | Six treatment groups were assessed for safety and pharmacokinetics. HRX215 was rapidly absorbed and showed biphasic elimination without significant blood-count differences. These are early safety data, not proof of clinical efficacy. | Zwirner et al., 2024; EudraCT 2021-000193-28, https://doi.org/10.1016/j.cell.2024.02.023 (zwirner2024firstinclassmkk4inhibitors pages 11-13, zwirner2024firstinclassmkk4inhibitors pages 1-3) |
Table: Concise evidence matrix linking human MAP2K4 identity and molecular function to direct experiments, cancer context, and the 2024 HRX215 translational program. It distinguishes well-established catalytic annotations from localization caveats and early clinical findings.
High-confidence annotations are the identity of P45985 as human MKK4, its MAP2K/STE kinase architecture, activation at Ser257/Thr261, direct JNK/p38 phosphorylation, JNK Tyr185 preference, N-terminal MAPK docking and its position between stress-responsive MAP3Ks and JNK/p38. These conclusions are supported by structural, biochemical and mutational evidence. (ho2003adockingsite pages 1-1, katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, gehi2022intrinsicdisorderin pages 17-18)
Moderate-confidence, context-dependent annotations include exact compartmental dominance, immune-cell phenotypes and whether MAP2K4 is tumor suppressive or tumor promoting in a particular cancer. These require cell-type- and stimulus-resolved interpretation. (katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4, ahn2011map2k4functionsas pages 1-2, katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2)
Promising but not clinically established is MKK4 inhibition for liver regeneration. The 2024 mouse, pig and phase-I results are unusually strong translational evidence, but controlled patient efficacy, perioperative safety, infection/inflammation effects and long-term oncological safety remain to be established. (zwirner2024firstinclassmkk4inhibitors pages 11-13, zwirner2024firstinclassmkk4inhibitors pages 10-11, zwirner2024firstinclassmkk4inhibitors pages 3-5, tchorz2024prometheus2.0druginduced pages 1-2)
References
(katzengruber2023mkk4inhibitors—recentdevelopment pages 1-2): Leon Katzengruber, Pascal Sander, and Stefan A. Laufer. Mkk4 inhibitors—recent development status and therapeutic potential. International Journal of Molecular Sciences, 24:7495, Apr 2023. URL: https://doi.org/10.3390/ijms24087495, doi:10.3390/ijms24087495. This article has 26 citations.
(gehi2022intrinsicdisorderin pages 15-17): Bhuvaneshwari R. Gehi, Kundlik Gadhave, Vladimir N. Uversky, and Rajanish Giri. Intrinsic disorder in proteins associated with oxidative stress-induced jnk signaling. Cellular and Molecular Life Sciences, Mar 2022. URL: https://doi.org/10.1007/s00018-022-04230-4, doi:10.1007/s00018-022-04230-4. This article has 23 citations and is from a domain leading peer-reviewed journal.
(gehi2022intrinsicdisorderin pages 17-18): Bhuvaneshwari R. Gehi, Kundlik Gadhave, Vladimir N. Uversky, and Rajanish Giri. Intrinsic disorder in proteins associated with oxidative stress-induced jnk signaling. Cellular and Molecular Life Sciences, Mar 2022. URL: https://doi.org/10.1007/s00018-022-04230-4, doi:10.1007/s00018-022-04230-4. This article has 23 citations and is from a domain leading peer-reviewed journal.
(ho2003adockingsite pages 1-1): David T. Ho, A.Jane Bardwell, Mahsa Abdollahi, and Lee Bardwell. A docking site in mkk4 mediates high affinity binding to jnk mapks and competes with similar docking sites in jnk substrates*. Journal of Biological Chemistry, 278:32662-32672, Aug 2003. URL: https://doi.org/10.1074/jbc.m304229200, doi:10.1074/jbc.m304229200. This article has 145 citations and is from a domain leading peer-reviewed journal.
(katzengruber2023mkk4inhibitors—recentdevelopment pages 2-4): Leon Katzengruber, Pascal Sander, and Stefan A. Laufer. Mkk4 inhibitors—recent development status and therapeutic potential. International Journal of Molecular Sciences, 24:7495, Apr 2023. URL: https://doi.org/10.3390/ijms24087495, doi:10.3390/ijms24087495. This article has 26 citations.
(zwirner2024firstinclassmkk4inhibitors pages 11-13): Stefan Zwirner, Anan A. Abu Rmilah, Sabrina Klotz, Bent Pfaffenroth, Philip Kloevekorn, Athina A. Moschopoulou, Svenja Schuette, Mathias Haag, Roland Selig, Kewei Li, Wei Zhou, Erek Nelson, Antti Poso, Harvey Chen, Bruce Amiot, Yao Jia, Anna Minshew, Gregory Michalak, Wei Cui, Elke Rist, Thomas Longerich, Birgit Jung, Philipp Felgendreff, Omelyan Trompak, Prem K. Premsrirut, Katharina Gries, Thomas E. Muerdter, Georg Heinkele, Torsten Wuestefeld, David Shapiro, Markus Weissbach, Alfred Koenigsrainer, Bence Sipos, Eiso AB, Magdalena Ortiz Zacarias, Stephan Theisgen, Nicole Gruenheit, Saskia Biskup, Matthias Schwab, Wolfgang Albrecht, Stefan Laufer, Scott Nyberg, and Lars Zender. First-in-class mkk4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187:1666-1684.e26, Mar 2024. URL: https://doi.org/10.1016/j.cell.2024.02.023, doi:10.1016/j.cell.2024.02.023. This article has 73 citations and is from a highest quality peer-reviewed journal.
(zwirner2024firstinclassmkk4inhibitors pages 10-11): Stefan Zwirner, Anan A. Abu Rmilah, Sabrina Klotz, Bent Pfaffenroth, Philip Kloevekorn, Athina A. Moschopoulou, Svenja Schuette, Mathias Haag, Roland Selig, Kewei Li, Wei Zhou, Erek Nelson, Antti Poso, Harvey Chen, Bruce Amiot, Yao Jia, Anna Minshew, Gregory Michalak, Wei Cui, Elke Rist, Thomas Longerich, Birgit Jung, Philipp Felgendreff, Omelyan Trompak, Prem K. Premsrirut, Katharina Gries, Thomas E. Muerdter, Georg Heinkele, Torsten Wuestefeld, David Shapiro, Markus Weissbach, Alfred Koenigsrainer, Bence Sipos, Eiso AB, Magdalena Ortiz Zacarias, Stephan Theisgen, Nicole Gruenheit, Saskia Biskup, Matthias Schwab, Wolfgang Albrecht, Stefan Laufer, Scott Nyberg, and Lars Zender. First-in-class mkk4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187:1666-1684.e26, Mar 2024. URL: https://doi.org/10.1016/j.cell.2024.02.023, doi:10.1016/j.cell.2024.02.023. This article has 73 citations and is from a highest quality peer-reviewed journal.
(zwirner2024firstinclassmkk4inhibitors pages 3-5): Stefan Zwirner, Anan A. Abu Rmilah, Sabrina Klotz, Bent Pfaffenroth, Philip Kloevekorn, Athina A. Moschopoulou, Svenja Schuette, Mathias Haag, Roland Selig, Kewei Li, Wei Zhou, Erek Nelson, Antti Poso, Harvey Chen, Bruce Amiot, Yao Jia, Anna Minshew, Gregory Michalak, Wei Cui, Elke Rist, Thomas Longerich, Birgit Jung, Philipp Felgendreff, Omelyan Trompak, Prem K. Premsrirut, Katharina Gries, Thomas E. Muerdter, Georg Heinkele, Torsten Wuestefeld, David Shapiro, Markus Weissbach, Alfred Koenigsrainer, Bence Sipos, Eiso AB, Magdalena Ortiz Zacarias, Stephan Theisgen, Nicole Gruenheit, Saskia Biskup, Matthias Schwab, Wolfgang Albrecht, Stefan Laufer, Scott Nyberg, and Lars Zender. First-in-class mkk4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187:1666-1684.e26, Mar 2024. URL: https://doi.org/10.1016/j.cell.2024.02.023, doi:10.1016/j.cell.2024.02.023. This article has 73 citations and is from a highest quality peer-reviewed journal.
(zwirner2024firstinclassmkk4inhibitors pages 1-3): Stefan Zwirner, Anan A. Abu Rmilah, Sabrina Klotz, Bent Pfaffenroth, Philip Kloevekorn, Athina A. Moschopoulou, Svenja Schuette, Mathias Haag, Roland Selig, Kewei Li, Wei Zhou, Erek Nelson, Antti Poso, Harvey Chen, Bruce Amiot, Yao Jia, Anna Minshew, Gregory Michalak, Wei Cui, Elke Rist, Thomas Longerich, Birgit Jung, Philipp Felgendreff, Omelyan Trompak, Prem K. Premsrirut, Katharina Gries, Thomas E. Muerdter, Georg Heinkele, Torsten Wuestefeld, David Shapiro, Markus Weissbach, Alfred Koenigsrainer, Bence Sipos, Eiso AB, Magdalena Ortiz Zacarias, Stephan Theisgen, Nicole Gruenheit, Saskia Biskup, Matthias Schwab, Wolfgang Albrecht, Stefan Laufer, Scott Nyberg, and Lars Zender. First-in-class mkk4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187:1666-1684.e26, Mar 2024. URL: https://doi.org/10.1016/j.cell.2024.02.023, doi:10.1016/j.cell.2024.02.023. This article has 73 citations and is from a highest quality peer-reviewed journal.
(ho2003adockingsite pages 1-2): David T. Ho, A.Jane Bardwell, Mahsa Abdollahi, and Lee Bardwell. A docking site in mkk4 mediates high affinity binding to jnk mapks and competes with similar docking sites in jnk substrates*. Journal of Biological Chemistry, 278:32662-32672, Aug 2003. URL: https://doi.org/10.1074/jbc.m304229200, doi:10.1074/jbc.m304229200. This article has 145 citations and is from a domain leading peer-reviewed journal.
(ho2003adockingsite pages 3-4): David T. Ho, A.Jane Bardwell, Mahsa Abdollahi, and Lee Bardwell. A docking site in mkk4 mediates high affinity binding to jnk mapks and competes with similar docking sites in jnk substrates*. Journal of Biological Chemistry, 278:32662-32672, Aug 2003. URL: https://doi.org/10.1074/jbc.m304229200, doi:10.1074/jbc.m304229200. This article has 145 citations and is from a domain leading peer-reviewed journal.
(zhao2026advancesinsmallmolecule pages 3-5): Min Zhao, Baojian Li, Ying Gao, Yan Liang, Nanqi Shao, Xinbo Shi, and Jie Li. Advances in small-molecule inhibitors of mkk4 and mkk7: from structural biology to therapeutic applications. Unknown journal, Jan 2026. URL: https://doi.org/10.20944/preprints202601.2001.v1, doi:10.20944/preprints202601.2001.v1.
(ahn2011map2k4functionsas pages 1-2): Young-Ho Ahn, Yanan Yang, Don L. Gibbons, Chad J. Creighton, Fei Yang, Ignacio I. Wistuba, Wei Lin, Nishan Thilaganathan, Cristina A. Alvarez, Jonathon Roybal, Elizabeth J. Goldsmith, Cathy Tournier, and Jonathan M. Kurie. map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Nov 2011. URL: https://doi.org/10.1128/mcb.05562-11, doi:10.1128/mcb.05562-11. This article has 89 citations and is from a domain leading peer-reviewed journal.
(ahn2011map2k4functionsas pages 4-5): Young-Ho Ahn, Yanan Yang, Don L. Gibbons, Chad J. Creighton, Fei Yang, Ignacio I. Wistuba, Wei Lin, Nishan Thilaganathan, Cristina A. Alvarez, Jonathon Roybal, Elizabeth J. Goldsmith, Cathy Tournier, and Jonathan M. Kurie. map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Nov 2011. URL: https://doi.org/10.1128/mcb.05562-11, doi:10.1128/mcb.05562-11. This article has 89 citations and is from a domain leading peer-reviewed journal.
(ahn2011map2k4functionsas pages 2-4): Young-Ho Ahn, Yanan Yang, Don L. Gibbons, Chad J. Creighton, Fei Yang, Ignacio I. Wistuba, Wei Lin, Nishan Thilaganathan, Cristina A. Alvarez, Jonathon Roybal, Elizabeth J. Goldsmith, Cathy Tournier, and Jonathan M. Kurie. map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Nov 2011. URL: https://doi.org/10.1128/mcb.05562-11, doi:10.1128/mcb.05562-11. This article has 89 citations and is from a domain leading peer-reviewed journal.
(OpenTargets Search: -MAP2K4): Open Targets Query (-MAP2K4, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(zwirner2024firstinclassmkk4inhibitors pages 7-8): Stefan Zwirner, Anan A. Abu Rmilah, Sabrina Klotz, Bent Pfaffenroth, Philip Kloevekorn, Athina A. Moschopoulou, Svenja Schuette, Mathias Haag, Roland Selig, Kewei Li, Wei Zhou, Erek Nelson, Antti Poso, Harvey Chen, Bruce Amiot, Yao Jia, Anna Minshew, Gregory Michalak, Wei Cui, Elke Rist, Thomas Longerich, Birgit Jung, Philipp Felgendreff, Omelyan Trompak, Prem K. Premsrirut, Katharina Gries, Thomas E. Muerdter, Georg Heinkele, Torsten Wuestefeld, David Shapiro, Markus Weissbach, Alfred Koenigsrainer, Bence Sipos, Eiso AB, Magdalena Ortiz Zacarias, Stephan Theisgen, Nicole Gruenheit, Saskia Biskup, Matthias Schwab, Wolfgang Albrecht, Stefan Laufer, Scott Nyberg, and Lars Zender. First-in-class mkk4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187:1666-1684.e26, Mar 2024. URL: https://doi.org/10.1016/j.cell.2024.02.023, doi:10.1016/j.cell.2024.02.023. This article has 73 citations and is from a highest quality peer-reviewed journal.
(tchorz2024prometheus2.0druginduced pages 1-2): Jan S. Tchorz. Prometheus 2.0: drug-induced liver regeneration arising. Cell research, 34:541-542, Apr 2024. URL: https://doi.org/10.1038/s41422-024-00965-w, doi:10.1038/s41422-024-00965-w. This article has 2 citations and is from a domain leading peer-reviewed journal.
(zwirner2024firstinclassmkk4inhibitors pages 32-38): Stefan Zwirner, Anan A. Abu Rmilah, Sabrina Klotz, Bent Pfaffenroth, Philip Kloevekorn, Athina A. Moschopoulou, Svenja Schuette, Mathias Haag, Roland Selig, Kewei Li, Wei Zhou, Erek Nelson, Antti Poso, Harvey Chen, Bruce Amiot, Yao Jia, Anna Minshew, Gregory Michalak, Wei Cui, Elke Rist, Thomas Longerich, Birgit Jung, Philipp Felgendreff, Omelyan Trompak, Prem K. Premsrirut, Katharina Gries, Thomas E. Muerdter, Georg Heinkele, Torsten Wuestefeld, David Shapiro, Markus Weissbach, Alfred Koenigsrainer, Bence Sipos, Eiso AB, Magdalena Ortiz Zacarias, Stephan Theisgen, Nicole Gruenheit, Saskia Biskup, Matthias Schwab, Wolfgang Albrecht, Stefan Laufer, Scott Nyberg, and Lars Zender. First-in-class mkk4 inhibitors enhance liver regeneration and prevent liver failure. Cell, 187:1666-1684.e26, Mar 2024. URL: https://doi.org/10.1016/j.cell.2024.02.023, doi:10.1016/j.cell.2024.02.023. This article has 73 citations and is from a highest quality peer-reviewed journal.